UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

grivet ABCB1

Synonyms: p-glycoprotein

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

No expression data.


Back to top

In Vitro Substrates

No substrate information.


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
(+)-devapamil 1.3 Vinblastine COS-7 cells Hollt, 1992
(+)-emopamil 3.8 Vinblastine COS-7 cells Hollt, 1992
(+)-felodipine 19.6 Vinblastine COS-7 cells Hollt, 1992
(+)-isradipine 6.9 Vinblastine COS-7 cells Hollt, 1992
(+)-niguldipine 1.1 Vinblastine COS-7 cells Hollt, 1992
(+)-nimodipine 5.2 Vinblastine COS-7 cells Hollt, 1992
(+)-nitrendipine 5.7 Vinblastine COS-7 cells Hollt, 1992
(+)-verapamil 1.6 Vinblastine COS-7 cells Hollt, 1992
(-)-devapamil 3.7 Vinblastine COS-7 cells Hollt, 1992
(-)-emopamil 3.7 Vinblastine COS-7 cells Hollt, 1992
(-)-felodipine 19.2 Vinblastine COS-7 cells Hollt, 1992
(-)-isradipine 4 Vinblastine COS-7 cells Hollt, 1992
(-)-niguldipine 1.1 Vinblastine COS-7 cells Hollt, 1992
(-)-nimodipine 6.7 Vinblastine COS-7 cells Hollt, 1992
(-)-nitrendipine 8.6 Vinblastine COS-7 cells Hollt, 1992
(-)-verapamil 2.4 Vinblastine COS-7 cells Hollt, 1992
B869-60 67.8 Vinblastine COS-7 cells Hollt, 1992
B869-61 51.3 Vinblastine COS-7 cells Hollt, 1992
Bay K 8644 100 Vinblastine COS-7 cells Hollt, 1992
Gallopamil 2.4 Vinblastine COS-7 cells Hollt, 1992
Nifedipine 74 Vinblastine COS-7 cells Hollt, 1992

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner